Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BMP4 | P12644 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485626 | 1.00 | KDM4E (0.45) | KDM4EHPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL28182837 | 0.98 | KDM4E (0.44) | KDM4EHPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL30119859 | 0.77 | MAPT (0.50) | KDM4EMAPTMEN1LMNAKMT2A | |
| SCHEMBL1370432 | 0.77 | MAPT (0.50) | KDM4EMAPTMEN1LMNAKMT2A | |
| SCHEMBL31038802 | 0.76 | MAOB (0.36) | KDM4EMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL15644331 | 0.76 | NUDT1 (0.35) | KDM4ENPC1MAPTLMNAKMT2A | |
| SCHEMBL17732805 | 0.75 | IKBKB (0.41) | KDM4EMAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL30494729 | 0.73 | KDM4E (0.51) | KDM4EHPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL11922160 | 0.72 | TNKS (0.40) | MEN1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL9263010 | 0.72 | PDPK1 (0.34) | RAB9ANPC1MAPTSMN1; SMN2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0594883-B1 | Imidazo(1,2-c) quinazoline derivatives as antihypertensives and anti dysurics | NAT SCIENCE COUNCIL (TW) | 1999-01-27 | — | — | EP | claimed |
| EP-0446141-B1 | Imidazo[1,2-c]quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-01-18 | — | — | EP | claimed |
| US-5340814-A | Hypotensive agents | NATIONAL SCIENCE COUNCIL (TW) | 1994-08-23 | — | — | US | claimed |
| EP-0594883-A1 | Imidazo(1,2-c) quinazoline derivatives as antihypertensives and anti dysurics | NATIONAL SCIENCE COUNCIL (TW) | 1994-05-04 | — | — | EP | claimed |
| EP-0594877-A1 | Imidazo(1,2-c)quinazoline derivates as antihyper tensives and anti dysurics | NATIONAL SCIENCE COUNCIL (TW) | 1994-05-04 | — | — | EP | claimed |
| US-5158953-A | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof | NATIONAL SCIENCE COUNCIL (TW) | 1992-10-27 | — | — | US | claimed |
| US-5128338-A | Cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1992-07-07 | — | — | US | claimed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-9169282-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169282-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169282-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| WO-2013000531-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-01-03 | — | — | WO | disclosed |
| EP-0491814-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | NOVO NORDISK AS (DK) | 1992-07-01 | — | — | EP | disclosed |
| US-5100895-A | Imidazoquinazoline compounds; anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, improving cognitive function | NOVO NORDISK A/S (DK) | 1992-03-31 | — | — | US | disclosed |
| WO-1992004351-A1 | CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0446141-A1 | Imidazo[1,2-c]quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991003478-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK A/S (DK) | 1991-03-21 | — | — | WO | disclosed |
| EP-0417027-A1 | Tetracyclic imidazoquinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | NOVO NORDISK A/S (DK) | 1991-03-13 | — | — | EP | disclosed |
| EP-0046446-A1 | Polyazaheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | ADORA2A, ADORA3, ADORA1 | KDM4E 3642/4885HPGD 3019/4885HSD17B10 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.